美罗华的有效性与ocrelizumab原发性进行性多发性硬化症的治疗:一个真实的观察研究。

文章的细节

引用

复制到剪贴板

Alcala C, Quintanilla-Bordas C、F吹牛的人,Sempere美联社,纳瓦罗L, Carcelen-Gadea M, Landete L, Mallada J, Canizares E, Belenguer, Carratala年代,Dominguez是的,Perez-Miralles FC, Gil-Perotin年代,Gasque R,不同的古巴L,卡斯蒂略J,卡萨诺瓦B

美罗华的有效性与ocrelizumab原发性进行性多发性硬化症的治疗:一个真实的观察研究。

J神经。2022年7月,269 (7):3676 - 3681。doi: 10.1007 / s00415 - 022 - 10989 - 0。Epub 2022 2月2。

PubMed ID

35107597 (在PubMed

]

文摘

简介:Ocrelizumab antiCD-20抗体,是唯一批准药物治疗原发性进行性多发性硬化症患者(pwPPMS)。并不是所有候选人接受这个治疗处方的局限性。另一个antiCD-20抗体美罗华标示外使用前后pwPPMS ocrelizumab批准。然而,研究比较两种药物的有效性缺乏。摘要目的:评价的有效性利妥昔单抗和ocrelizumab pwPPMS在现实条件下。方法:我们进行了一项多中心观察研究开始ocrelizumab或利妥昔单抗的pwPPMS根据临床实践,至少随访1年。数据收集的前瞻性和回顾性。主要结果在3个月时间来证实残疾进展(CDW)。二次结果血清神经丝轻链(sNFL)随访结束时的水平。结果:95 111 pwPPMS满足入选标准和后续的数据可用性:49(51.6%)接受利妥昔单抗和46 ocrelizumab (48.4%)。 Rituximab-treated patients had significantly higher baseline EDSS, disease duration and history of previous disease-modifying treatment (DMT) than ocrelizumab-treated patients. After a mean follow-up of 18.3 months (SD 5.9), 26 patients experienced CDW (21.4%); 15 (30.6%) in the rituximab group; and 11 (23.9%) in the ocrelizumab group. Survival analysis revealed no differences in time to CDW. sNFL were measured in 60 patients and no differences between groups were found. INTERPRETATION: We provide real-world evidence of effectiveness of ocrelizumab and rituximab in pwPPMS. No differences in time to CDW were found between treatments. However, this study cannot establish equivalence of treatments and warrant clinical trial to confirm our findings.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Ocrelizumab